19070-16-7

Basic information

• Product Name: CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM
• Synonyms: CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM
• CAS NO: 19070-16-7
• Molecular Formula: C₅H₁₂ClMgN
• Molecular Weight: 0
• Mol File: 19070-16-7.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM(CAS DataBase Reference)
• NIST Chemistry Reference: CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM(19070-16-7)
• EPA Substance Registry System: CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM(19070-16-7)

Safety Data

• Hazardous Substances Data: 19070-16-7(Hazardous Substances Data)

Usage

General Description

Chloro[3-(dimethylamino)propyl]magnesium is a chemical compound with an interesting arrangement of atoms and functional groups. It contains chlorine, magnesium, and the functional group -N(CH3)2, also known as a dimethylamino group. This functional group is attached to a three-carbon propyl group. As an organomagnesium compound, it may behave as a strong base and nucleophile, potentially making it useful in certain chemical reactions. Specific properties such as its physical state, color, odor, melting point, boiling point, density, solubility, and stability under various conditions may vary depending on its precise formulation and any stabilizing agents that may be added. Its applications and safety measures would depend on these characteristics and the specific ways in which the compound is used.

InChI:InChI=1/C5H12N.ClH.Mg/c1-4-5-6(2)3;;/h1,4-5H2,2-3H3;1H;/q;;+1/p-1/rC5H12ClMgN/c1-8(2)5-3-4-7-6/h3-5H2,1-2H3

Upstream product

• 109-54-6 3-(Dimethylamino)propyl chloride 
• 6203-08-3 methyl 5-norbornene-2-carboxylate 
• 5407-04-5 3-(dimethylamino)propyl chloride hydrochloride 
• 3481-02-5 cyclopropyl phenyl ketone 
• 59795-23-2 10,11-dihydro-10,10,11,11-tetrafluoro-5H-dibenzo[a,d]cyclohepten-5-one 
• 113836-39-8 2-(4,4-dimethyl-2-oxazolin-2-yl)-11-oxo-6,11-dihydrodibenzoxepin 
• 113836-41-2 11-oxo-2-<2-<(triphenylmethyl)oxy>ethyl>-6,11-dihydroxydibenzoxepin 

Downstream Products

• 521-80-2 N,N-dimethyl-3-(5H-dibenzo[a,d]cyclohepten-5-yl)-propylamine 
• 1229-29-4 doxepin hydrochloride 
• 488148-10-3 4-(4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzobromide 
• 59729-33-8 1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile 
• 59729-32-7 citalopram hydrobromide 
• 128196-01-0 escitalopram 
• 219861-08-2 escitalopram oxalate 
• 917483-01-3 (R)-4-(4-dimethylamino-1-(4'-fluorophenyl)-1-hydroxybutyl)-3-hydroxymethylbenzonitrile, salt with (+)-O,O'-di-p-toluoyltartaric acid 
• 128173-53-5 4-(1S)-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile (+)-di-(p-toluoyl)tartaric acid 
• 103146-26-5 4-(4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile hydrobromide 
• 717133-25-0 citalopram diol hydrochloride 
• 85118-29-2 C₂₁H₂₇NO 
• 103146-25-4 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile 
• 1329745-98-3 (R)-4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)-1-butanone 

Relevant articles and documents

Synthesis of new heteroleptic strontium complexes

A series of heteroleptic strontium complexes (1-9) using a combination of different aminoalkoxides and 2,2,6,6-tetramethyl-3,5-heptanedionate (tmhd) were prepared to examine the effect of the bulkiness and coordination ability of the aminoalkoxide ligand in these complexes as well as potential strontium precursors. All complexes were characterized by FT-IR, FT-NMR, elemental analyses, and thermo-gravimetric (TG) analyses. The crystal structure analyses of 1, 2, 4, and 5 demonstrate their stability in the dimer form and the unwillingness of the strontium atom to form more than six coordination bonds in these complexes. The complex 5 shows an unusual picture: the existence of one hexa-coordinated and one penta-coordinated strontium atom side by side in its dimer structure. The introduction of ether groups as coordination sites in complexes 6-9 led to a decrease in steric hindrance which resulted in the formation of the complex 7 as a tetramer. The complex 7 shows a unique Sr4O4cubane core where oxygen atoms undergo μ3-bridging between strontium atoms. The TG analyses show that the complexes exhibit a step-wise decomposition character, with the major mass losses in the region 150-400 °C.

NOVEL PHTHALOCYANINE DERIVATIVES FOR THERAPEUTIC USE

There are described phthalocyanine derivates, the pharmaceutical compositions and the medical devices that contain them, possibly in combination with chelating agents, such as EDTA, useful for treating, by means of photodynamic therapy, diseases character

Preparation of Escitalopram, Its Salts and Intermediates

The present patent application relates to an improved process for the preparation of escitalopram, its salts and intermediates. It also relates to a novel crystalline form S of citalopram diol intermediate, process for preparation and its use in the preparation of citalopram, escitalopram and their salts.